【摘要】

【摘要】目的：研究富马酸喹硫平片应用于精神分裂症的临床效果及安全性。
方法：选取我院收治的100例精神分裂症患者作为观察对象，将其随机分为观察组、对照组，两组各50例。对照组给予口服奥氮平片治疗，根据治疗效果改变用药量。实验组在对照组治疗基础上口服富马酸喹硫平片，用药量改变与对照组相同。观察患者疗效、认知功能及不良反应。
结果：实验组治疗总有效率为95.37％，高于对照组的79.05%，差异有统计学意义（P<0.05）；治疗前，两组患者认知功能评分比较，差异均无统计学意义(P>0.05)；经相应治疗，两组患者认知功能评分均显著高于同组治疗前，随治疗时间的延长逐渐升高，且观察组高于对照组，差异均有统计学意义(P<0.05)；实验组不良反应总发生率为12.0%，低于对照组的32.0%，差异有统计学意义（P<0.05）。
结论：富马酸喹硫平片对于精神分裂症有较好的治疗效果，安全性相对较高，值得临床推广。

【Abstract】

[Abstract] Objective: to study the clinical effect and safety of quetiapine fumarate tablets in the treatment of schizophrenia.
Methods: 100 patients with schizophrenia were randomly divided into observation group and control group, 50 cases in each group. The control group was treated with oral olanzapine tablets, and the dosage was changed according to the therapeutic effect. The experimental group was treated with quetiapine fumarate tablets on the basis of the control group, the dosage change was the same as the control group. To observe the efficacy, cognitive function and adverse reactions of patients.
Results: the total effective rate was 95.37 % in the experimental group, which was higher than that in the control group ( 79.05 % ) ( p < 0.05 ). Before treatment, there was no significant difference in cognitive function between the two groups ( p > 0.05 ). After treatment, the cognitive function score of the two groups was significantly higher than that of the same group before treatment, and increased gradually with the treatment time, and the observation group was higher than the control group, the difference was statistically significant ( p < 0.05 ); The total incidence of adverse reactions in the experimental group was 12.0 %, which was lower than that in the control group ( 32.0 % ) ( p < 0.05 ).
Conclusion  : the quetiapine fumarate tablets have a better therapeutic effect on schizophrenia, and the safety is relatively high, which is worthy of clinical promotion.